H2020-JTI-IMI-2018

Progress novel assets (one FTIH start) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline and cytochrome bc drugs

Functional Ethionamide boosters: a novel combination for tuberculosis therapy

Infection site targeting, antibiotic encapsulated in nanoparticles for treating extracellular bacterial infections

AMR Accelerator programme Pillar A: Capability Building Network to accelerate and validate scientific discoveries

Development and validation of translational platforms in support of synaptopathy drug discovery

AMR Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic

Determination of gepotidacin levels in tonsils and prostatic tissue

Microenvironment imposed signatures in tissue and liquid biopsies in immune- mediated diseases

Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for TB that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Integrated research platforms enabling patient-centric drug development

Digital endpoints in neurodegenerative and immune-mediated diseases

Blockchain Enabled Healthcare

Development of a platform for federated and privacy-preserving machine learning in support of drug discovery

Targeted immune intervention for the management of non-response and relapse

Centre Of Excellence – Remote Decentralised Clinical Trials

Non-invasive clinical molecular imaging of immune cells